Analysts Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $13.97

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been given a consensus rating of “Buy” by the nine brokerages that are presently covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $13.97.

Several brokerages recently weighed in on VYGR. Cantor Fitzgerald reiterated an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Finally, Wedbush reissued an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th.

Voyager Therapeutics Trading Up 3.6 %

NASDAQ:VYGR opened at $3.49 on Monday. The stock has a 50 day moving average of $3.68 and a 200-day moving average of $5.24. The firm has a market capitalization of $192.67 million, a PE ratio of 4.92 and a beta of 1.02. Voyager Therapeutics has a 52 week low of $2.75 and a 52 week high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. During the same quarter in the previous year, the company earned $1.25 earnings per share. As a group, analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Activity

In other news, CEO Alfred Sandrock sold 10,885 shares of the company’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares of the company’s stock, valued at $1,478,093.33. This represents a 2.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors have recently bought and sold shares of VYGR. Cubist Systematic Strategies LLC acquired a new position in shares of Voyager Therapeutics in the fourth quarter worth about $29,000. Tower Research Capital LLC TRC boosted its stake in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management grew its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares in the last quarter. Oxford Asset Management LLP acquired a new stake in Voyager Therapeutics during the 4th quarter valued at $60,000. Finally, Tema Etfs LLC purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at $85,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.